Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
About Apyx Medical Corporation
Apyx Medical Corporation (NASDAQ: APYX) is an advanced energy technology company specializing in the development, manufacturing, and marketing of innovative medical devices for the cosmetic and surgical markets worldwide. With a strong focus on leveraging proprietary technologies, Apyx delivers cutting-edge solutions that elevate surgical precision and aesthetic outcomes.
The company operates through two primary business segments: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment is centered around its patented Helium Plasma Platform Technology, which is marketed under the Renuvion brand name in the cosmetic surgery market and as J-Plasma in the hospital surgical market. These technologies enable surgeons to achieve unparalleled precision in cutting, coagulation, and ablation of soft tissue while minimizing unintended tissue trauma. The Renuvion system, in particular, empowers plastic surgeons, facial plastic surgeons, and cosmetic physicians to deliver controlled heat to tissue, enhancing patient outcomes in body contouring and other aesthetic procedures.
In addition to its proprietary technologies, Apyx's OEM segment designs, develops, and manufactures electrosurgical generators and related accessories for other medical device manufacturers. This segment leverages the company's decades of expertise in advanced waveforms, allowing it to establish strategic partnerships and diversify its revenue streams.
Industry Position and Market Impact
Apyx Medical Corporation operates at the intersection of the medical device and cosmetic surgery industries, addressing a growing demand for minimally invasive and precise surgical solutions. The company's Renuvion and J-Plasma technologies are supported by extensive clinical validation, with over 90 published clinical documents attesting to their efficacy and safety. This robust evidence base enhances the company's credibility and fosters trust among surgeons and patients alike.
By focusing on innovation and quality, Apyx distinguishes itself in a competitive landscape that includes other advanced energy technology providers. Its ability to address both cosmetic and surgical applications positions it uniquely within its market segments, catering to a diverse customer base that spans hospitals, surgery centers, and private practices.
Commitment to Innovation and Quality
As a company formerly known as Bovie Medical Corporation, Apyx has a legacy of expertise in energy-based medical technologies. Its ongoing commitment to research and development ensures that it remains at the forefront of surgical innovation. By integrating advanced technology with user-centric design, Apyx continues to enhance the capabilities of surgeons and improve patient outcomes.
Conclusion
Apyx Medical Corporation exemplifies the convergence of innovation, precision, and clinical excellence in the medical device industry. Through its proprietary Helium Plasma Platform Technology and strategic OEM partnerships, the company addresses critical needs in both surgical and cosmetic markets. With a focus on delivering transformative solutions and maintaining rigorous quality standards, Apyx is well-positioned to drive meaningful advancements in the field of energy-based medical devices.
Apyx Medical reported a strong performance in Q4 2021, with total revenue reaching $16.8 million, a 47% increase year-over-year. Advanced Energy sales surged 52% to $15.0 million, while OEM revenue rose 13% to $1.8 million. Despite a net loss of $2.0 million, improved efficiencies reduced the adjusted EBITDA loss to $0.3 million. For 2022, guidance is set between $50.0 million to $63.0 million in total revenue, indicating potential growth of 3% to 30%.
Apyx Medical Corporation (NASDAQ:APYX) announced that the FDA intends to issue a Medical Device Safety Communication (MDSC) regarding its Advanced Energy products, specifically concerning their off-label use. The company emphasizes ongoing compliance and support for safe practices, despite some products being used for unapproved dermal resurfacing. Apyx continues to work with the FDA for 510(k) clearances for additional clinical indications and maintains its existing clearances. Since 2017, 90 medical device reports (MDRs) have been submitted, although these represent a small fraction of total procedures performed.
Apyx Medical Corporation (NASDAQ:APYX) announced the submission of an FDA 510(k) premarket notification for its Renuvion® Dermal Handpiece aimed at dermatological procedures requiring ablation and resurfacing. This follows the publication of a peer-reviewed study in Lasers in Surgery and Medicine, confirming that 100% of subjects experienced an improvement in wrinkle scores after treatment. The study reports high satisfaction rates and no serious adverse events, supporting Apyx's regulatory strategy and market expansion goals in the U.S. cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) is set to release its financial results for the fourth quarter and fiscal year 2021 on March 17th, before the market opening. A conference call will be held at 8:00 a.m. ET on the same day, allowing stakeholders to discuss the results and participate in a Q&A session. The call can be accessed via phone or a live webcast on the Company's website. A replay will be available until March 31, 2022.
Apyx Medical specializes in innovative medical devices, showcasing its Helium Plasma Technology.
Apyx Medical Corporation (NASDAQ:APYX) announced its preliminary revenue results for Q4 and full year 2021, revealing $16.3 to $16.8 million in Q4, a year-over-year growth of 42% to 46%.
Advanced Energy sales ranged from $14.7 to $15.0 million, indicating a 49% to 52% increase compared to last year. For the full year, total revenue reached $48.0 to $48.5 million, a growth of 73% to 75%. However, OEM revenue faced a slight decline.
CEO Charlie Goodwin highlighted strong adoption of their Renuvion® technology in the U.S., driving sales above expectations.
Apyx Medical Corporation (NASDAQ:APYX) reported strong Q3 2021 results, with total revenue reaching $11.8 million, a 70% increase year-over-year. Advanced Energy sales surged 88% to $10.3 million, driven by increased demand for Renuvion® products. Net loss attributable to stockholders was $4.2 million, slightly higher than $3.7 million in Q3 2020. Full year revenue guidance was raised to $44-45 million, reflecting a year-over-year growth of 59%-62%. As of September 30, 2021, the company held $30.9 million in cash and equivalents.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in several upcoming investor conferences. Events include virtual 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 16, a presentation at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 p.m. ET, and additional meetings at the Canaccord Genuity Forum on November 18. A fireside chat will be available on-demand at the Piper Sandler Conference starting November 22. Audio webcasts will be accessible on their investor relations website.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q3 FY2021 on November 11, 2021, after market closure. The Company specializes in medical devices using its Helium Plasma Technology, marketed as Renuvion® and J-Plasma®. A conference call will be held at 5:00 p.m. ET the same day to discuss these results. The call can be accessed by phone or via a live webcast. A telephonic replay will be available post-call. Apyx aims to enhance surgical precision and minimize tissue trauma with its innovative technology.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technologies, will participate in the Colliers Securities 2021 Institutional Investor Conference on September 9th, 2021. The event will be held virtually with management engaging in one-on-one meetings. Apyx is recognized for its innovative Helium Plasma Technology, marketed as Renuvion® in cosmetic surgery and J-Plasma® in the surgical market. These technologies enable precise tissue heating for enhanced surgical outcomes. For more details, visit www.ApyxMedical.com.
Apyx Medical Corporation (NASDAQ:APYX) has appointed Wendy Levine to its Board of Directors, effective August 25, 2021. Ms. Levine brings over 25 years of experience in healthcare marketing and advertising, having held leadership roles across various global healthcare companies including Johnson & Johnson and Novartis. CEO Charlie Goodwin expressed confidence in Ms. Levine's ability to enhance consumer marketing strategies for Apyx's innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma® in their respective markets.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are Apyx's primary product offerings?
How does Apyx generate revenue?
What markets does Apyx serve?
What differentiates Apyx from competitors?
What is the Renuvion system used for?
What is the J-Plasma system designed for?
What is Apyx's approach to innovation?
Does Apyx have strategic partnerships?
What is Apyx's legacy in the medical device industry?
